Thank you, Gordon, and good morning, everyone.
clinical from discussing these are believe wider set for I as data and need QRXXXX well across possibly plans clinical this result October culminating a protocol product. in more will pursuing to potentially in optimized now syndrome on result spend data fronts for multiple that for the amendments positive will robust Netizen the and the even ongoing a past development. this our an regulatory and progress trial quarter QRXXXX, faster additional which to we ended initial some data of approval quarter, positive of significant During time as updated as after we open-label XX. We in planned newly clinical make continued release this clinical our
into the commercial entered Southeast in agreement we we Singapore. Furthermore, to for discussions to an into similar as countries quarter, of with commercial This our enter commercial the entering agreement for partnerships will possible we QRXXXX number into into are to partnership approach product keeping Latin entered to the countries partnerships of This once that ninth QRXXXX countries increases that is available in During XX. for mission systematic currently as entirely in the have with additional FarmaMondo new for diligent many and signing in and be America. Asia our made many approved. patients partnerships spoken ensure as with to late-stage
be a own our underappreciated product somewhat noted global materially which our effectively company effectively represents network foundation will the that fall that the network The for a have our and a similar could highly perhaps future commercial and what is previously, firmly these for for and We global incremental advantage of receive to to this all opportunity commercial launches infrastructure will the approval. for revenue-generating line for with and represents unprecedented planned company lay amount profitability. partnerships, size As Europe will and on significant partnership bottom this positive Quoin. our differentiated approved potential once also for company ultimately commercial highly impact once believe facilitate they regulatory along pipeline U.S. global products of launch global also the our of the
updated call, I everyone on our last also M&A strategy. our During
focused or on portfolio expanding discussed, capital via our been strong As balance additional licensing needs. product and acquisition, sheet we have potential given access other to our acutely
an well we over different XX assessed where this year, opportunities. extensive broad-based and Following process throughout
we which that list narrowed products terms. for past on key successfully all the quarter, agreement During to specific ultimately we reached down financial X
we were are expeditiously least that the in guarantees as towards closing impacting the stated one out will transaction are we particular, as be transaction factors, at be previously, decisively there unfavorable working consummated no say can which possible. external least, to As actively have current there while market conditions, as
While want one I'm position our and We not can clear, I would provide a We all in these information that course.
I any specific hope in opportunities however. product to fully details on that do is visibility rare key additional not intend strongly X disease to assets. to the point fund clinical that portfolio. clear close the assets provide to out last complement as acquire tell assets make are due to to to do our enhance you products which The necessary development until ability raise have do company we these license thing clinical cannot our of. we the we on development support for such any a funds and will transaction current unless of
IND an received As FDA their for letter initiate stated have and clinical previous treatment we Proceed" another May "Study as with company the development calls, of now syndrome. a Netherton product has to potential the filed a on
we following still new application initiated of remains Quoin the and pattern some and an clinicaltrials.gov not that website, only other syndrome time further company has studies in INDs abandoned or initiating or either being Netherton syndrome while drug clinical morning, pushed completely. under see also those the to Netherton open further conducting of have INDs, investigation appears open a studies out under be for been this a indeed of As clinical timelines IND.
Furthermore, about to continue companies or it review of this actively spoken study filing consistent
be excited now the by marketing are the make opportunity significant partners and could more to regulatory clinical than first commercial front for horrendous As potential of the that we product what are global disease. ever X ourselves, we on approved progress continue this
many and new aspects and the only As not process but clinical product our that I'm our manufacturing development we have in has the stated, of as well. GMP manufacturer, CMO contract of our scaled CMC for development, peers, successfully ingredient a today active for the also announce to up the fully drug substance. pleased unlike biotech developed Quoin, on consistently of focuses on side QRXXXX
active ingredient may available. in and well-characterized never GMP a recall material indication been there source any previously that has approved You quality although a has as of molecule, very that been drug QRXXXX, for the no
As GMP is forward from mind a the of represents result positive available exclusively with ingredient that process the successful availability our collaboration for the of scaled-up our to longer product. the contractually fully the CMO, material Bear and manufacturing another material that source of only. development active case yet step in Quoin this no GMP in is of a
the intellectual be may this from new property also exciting developed development. are where We exploring actively
open-label to we ongoing This from patients. announced Turning our release On clinical from X Netherton studies of now syndrome first the in our evaluable was clinical in single-arm October data the subjects the data study. XX, study. positive
Recall date, subjects subjects conjunction As It measured receiving duration noting data that do will across so continue and the QRXXXX years, treatment, the endpoints. treatment entry study, for open-label outlined in significant at study, recruited Netherton on therapy this have been and positive in release was into in treated are study in off-label therapy with currently in worth to that the all point is the clear press compromised several study. that itch. systemic this for our the study of off-label systemic and exhibited systemic patients pruritus and notwithstanding for ongoing with multiple syndrome number least into a including cases year all of one at signs skin of or long-term the this this of
XX baseline a long-term duration to As into natural subjects of provided the across number with recruited therapeutic if treatment of a study clinical this end a points. lead therapy, for QRXXXX would result weeks systemic to any assess, improvement of us a over
low or was according system or to Absent subjects, after the As is standardized XX with defined their are absent scoring as X negligible or reported, to the for negligible X either score single-digit of X a treatment range. X in pruritus QRXXXX. pruritus itch very scoring
the For the pruritus particular the refractory in of possibly a subject, not from case. on with was this sixth uncommon of nature associated their reflecting pruritus effectively study, completion baseline unchanged their disease
off-label pruritus of baseline be X as largely X, distressing with pruritus disappeared those extremely is were had treatment We following experiencing these What receiving for noteworthy and subjects long-term extremely particularly therapy, X pruritus are QRXXXX. debilitating can is that that systemic despite Netherton for with pleased and patients. significant results all
the all X addition, In scoring system. in to skin investigator evaluated subjects according appearance demonstrated an improvement
as throughout in signs further For potentially is the on in endpoint evidence there well-defined completion of appearance points not of possible efficacy of improvement for completion of a of were testing. while various a on the for necessarily X at patients, treatment QRXXXX, of the to study, X according improvement skin This X was important there skin NS. QRXXXX though subjects this with the other dosing appearance
product. experience across QRXXXX with a satisfaction expressed assessed subjects leading overall number X all the to positive metrics also, Importantly a of with
you use for topical QRXXXX caregivers. applied to and notion, patients makes an attractive is and know, As easily user-friendly it which
body approvals amendment Finally, based Taking from profile and QRXXXX and on X% an ongoing the reported exciting were the a of data diverse our perspective number date and the has suggestive to of and studies. an the in will extremely developments an planned a new for date of decision dose potentially such been This protocol amendments. of our and also to of to developments optimization for from robust may for the profile no date these lower higher there significant clean move which led the is adverse study. into faster product.
These treatment I submitted clinical IND and some both phase, ultimately clinical evidence the double-blinded across our result believe to both enabling elimination set was together, even of safe provide this have importantly, a now study observed to One to favorable throughout highly more safety overall QRXXXX, and very is for open details the X% potentially for events dose disease. two generated us studies, to we efficacy safety a safety
as forward, Going the will become placebo it the study X-arm X% study double-blinded would of higher the a and instead comprised and such, X-arm is. that a study of dose current now
to with performance on the addition, deliver clinical we daily of dosing evidence generated Again, efficacy we once both product the of to maximizing from with clean all the in the twice potential observed more daily across the believe studies. has far, body endpoints. potential very twice dosing evidence of QRXXXX, clinical product based view the of the of a measured daily clinical robust conjunction are date, across to modifying frequency a In so safety a profile to
twice the Finally, new with the increased QRXXXX forward. tested subjects XX from XX current being going the in subjects dose to be open-label study number will daily with of all
QRXXXX with For to forward, dose of twice XX study in increased this This And from that frequency the a a test benefit at studies. will and study, be daily with once indeed be tested X% be the for both now blinded will now cohort a going an of enrolled both the placebo us increasing enabling against subjects twice means daily. to XX. being daily, to of subjects a therapeutic will a original number materials to X-leg studies evaluate subjects the lead does have cohort if dosing second dosed incremental dosed each the applied
results. in faster these progress, data third clinical developments result will our more approval to update believe and as with compelling protocol a ultimately financial for We in set. a our now new I and are ask on discuss in very QRXXXX these quarter excited Gordon operational we Netherton discussed, syndrome that amendments about Gordon? may programs With our
